Moxonidine: A review of its use in essential hypertension

Drugs

Volumn 66, Issue 4, 2006, Pages 477-496

  Fenton, Caroline ^a   Keating, Gillian M ^a   Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hypertension; Imidazoline I1 receptor; Metabolic syndrome; Moxonidine; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

AMLODIPINE; ATENOLOL; CILAZAPRIL; CLONIDINE; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; LORAZEPAM; METFORMIN; METOPROLOL; MOXONIDINE; NIFEDIPINE; NITRENDIPINE; RAMIPRIL; RILMENIDINE;

ANTIHYPERTENSIVE ACTIVITY; ASTHENIA; BACKACHE; BLOOD PRESSURE; BRONCHITIS; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG TOLERANCE; ERYSIPELAS; ESSENTIAL HYPERTENSION; FATIGUE; GLUCOSE TOLERANCE; HEADACHE; HEART HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MIGRAINE; NAUSEA; NONHUMAN; POSTMARKETING SURVEILLANCE; REVIEW; SYMPATHETIC TONE; UNSPECIFIED SIDE EFFECT; URTICARIA; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES;

EID: 33645747198     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666040-00006     Document Type: Review

References (67)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289 (18): 2363-9
2. ESH-ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-72
4. Brookes L. New definition of hypertension proposed [online]. Available from URL: http://www.medscape.com [Accessed 2005 Jun 9]
5. Prichard BNC, Owens CWI, Graham BR. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J Hum Hypertens 1997 Aug; 11 Suppl. 1: 29-45
6. Schaefer HG, Toublanc N, Weimann H-J. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998; 9 (7): 481-90
7. Chrisp P, Faulds D. Moxonidine: a review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992 Dec; 44: 993-1012
8. 1-imidazoline hypertenreceptor agonist. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S27-41
9. Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997 Jan; 15 Suppl. 1: 47-55
10. Schafers RF, Holzgreve H, Distler A, et al. Double blind, multicentre comparison of moxonidine and enalapril and their effects on blood pressure and left ventricular mass: results of the MOXENA study [abstract no. P1051]. J Hypertens 2002 Jun; 20 Suppl. 4: 249
11. Waters J, Ashford J, Jäger B, et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial Of Physiotens In Combination) study. J Clin Basic Cardiol 1999; 2 (2): 219-24
12. Kirch W, Hutt HJ, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990 Dec; 30 (12): 1088-95
13. Mitrovic V, Patyna W, Huting J, et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991 Dec; 5 (6): 967-72
14. 1- imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000 Jun; 35: 1264-9
15. Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988 Oct; 15 (4): 245-53
16. Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998 Oct; 12: 463-7
17. Doumas MN, Douma SN, Petidis KM, et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004 Dec; 6 (12): 682-9
18. Martina B, Surber C, Jakobi C, et al. Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild-to-moderate hypertension. Angiology 1998 Nov; 49: 897-901
19. Farsang C, Finta E, Kerkovits L, et al. Moxonidine possibly inhibits angiotensin converting enzyme inhibitor (ACEi)-induced cough in patients with essential hypertension: a multicentre, open pilot study [abstract no. P2.216]. J Hypertens 2003 Jun; 21 Suppl. 4: 183
20. Troussov V, Acsenov C. Moxonidine (Phisiotens) in treatment of hypertension in elderly patients with type 2 diabetes mellitus [abstract no. 2543]. Diabetes Metab 2003 Aug; 29 (4 Suppl.): 314
21. Aparina T, Britov A, Gomazkov O. Effects of enalapril and moxonidine on left ventricular hypertrophy in relation to insulin resistance in hypertensive patients [abstract no. P1.198]. J Hypertens 2003 Jun; 21 Suppl. 4: 75
22. Reznik L, Koval S, Koval D, et al. The effects of moxonidine long-term monotherapy on endothelial vasoactive factors in patients with hypertension [abstract no. 99]. J Hypertens 2003 Jun; 21 Suppl. 4: 336
23. Sanjuliani AF, Genelhu de Abreu V, Ueleres Braga J, et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol 2004; 7: 19-25
24. Orynchak MA, Neyko EM, Chovganyuk OS. Role of moxonidine in insulin secretion and endothelial dysfunction in the patients with insulin resistance [abstract no. P-538]. Am J Hypertens 2005 May 2; 18 (5): 202-3
25. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)
26. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999; 17 Suppl. 3: S29-35
27. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract 2004 Mar; Suppl. 139: 26-32
28. Jacob S, Klimm HJ, Rett K, et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004 Jun; 112 (6): 315-22
29. Strojek K, Grzeszczak W, Ǵorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001 Mar; 12: 602-5
30. Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004 Nov; 15 (11): 2902-7
31. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003 Sep; 21 (9): 1709-17
32. He MM, Abraham TL, Lindsay TJ, et al. Metabolism and disposition of the antihypertensive agent moxonidine in humans. Drug Metab Dispos 2003 Mar; 31 (3): 334-42
33. Wise SD, Chan C, Schaefer HG, et al. Quinidine does not affect the renal clearance of moxonidine. Br J Clin Pharmacol 2002 Sep; 54: 251-4
34. Pinthong D, Songsermsakul P, Rattanachamnong P, et al. The effects of imidazoline agents on the aggregation of human platelets. J Pharm Pharmacol 2004 Feb; 56 (2): 213-20
35. 1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br J Clin Pharmacol 2004 May; 57 (5): 545-51
36. El-Ayoubi R, Menaouar A, Gutkowska J, et al. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. Br J Pharmacol 2005 May; 45 (1): 50-6
37. Cao C, Kang CW, Kim SZ, et al. Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. Am J Physiol Heart Circ Physiol 2004; 287 (1): H150-6
38. Moreira TS, Takakura AC, Menani JV, et al. Central blockade of nitric oxide synthesis reduces moxonidine-induced hypotension. Br J Pharmacol 2004 Jun; 142 (4): 765-71
39. Solvay Healthcare Limited. Physiotens tablets 200, 300 & 400 micrograms: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Jun 13]
40. Levy BI. The importance of microcirculation and tissue perfusion in hypertension [in French]. Curr Med Res Opin 2005; 21 Suppl. 5: S1-6
41. Sleight P. The sympathetic nervous system in hypertension: differing effects of drug treatment. Eur Heart J 1998 Jun; 19 Suppl. F: 39-44
42. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005 Sep; 112 (17): 2735-52
43. Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003 Mar; 21 Suppl. 1: S25-30
44. Abelĺan J, Leal M, Herńandez-Meńarguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005 Jan; 67 Suppl. 93: S20-4
45. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004 Sep; 18 (9): 669-75
46. Frei M, Kuster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: 25-8
47. K̈uppers HE, J̈ager BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997 Jan; 15: 93-7
48. Prichard BNC, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002; 11 (3): 166-72
49. Prichard BNC, Kuster LJ, Hughes PR, et al. Dose relation of blood pressure reduction with moxonidine: findings from three placebo- and active-controlled randomized studies. J Clin Basic Cardiol 2003; 6: 49-51
50. Camilleri G, Portal B, Quiniou G, et al. Comparison of the antihypertensive efficacy of and tolerance to two imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy [in French]. Ann Cardiol Angeiol (Paris) 2001 Apr; 50 (3): 169-74
51. Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxomidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S45-9
52. Wolf R. The treatment of hypertensive patients with at calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S42-4
53. Feuring M, Cassel W, Thun B, et al. Moxonidine and ramipril in patients with hypertension and obstructive pulmonary disease. Clin Drug Invest 2000 Jul; 20: 19-24
54. Pl̈anitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987 Jan; 27 (1): 46-51
55. Pl̈anitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29 (6): 645-50
56. 1 receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227-40
57. Rayner B, Coetzer E. Moxonidine is effective for controlling blood pressure in patients with resistant hypertension [abstract]. Cardiovasc J S Afr 2005 Mar; 16 (2 Suppl. 1): 20
58. Martin U, Hill C, O'Mahony D. Use of moxonidine in elderly patients with resistant hypertension. J Clin Pharm Ther 2005 Oct; 30 (5): 433-7
59. Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5 (5): 659-67
60. Confirmation of the effectiveness and tolerability profile of the antihypertensive moxonidine: data from 14 post-marketing surveillance studies involving >91,000 patients. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)
61. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88 (6): 2399-403
62. Peverill RE. Hypertension guidelines, meta-analyses and clinical trials: do we assume too much? Med J Aust 2005; 182 (2): 82-4
63. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1543-8
64. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin 2004 Mar; 20 (3): 359-67
65. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22: 1845-7
66. Kaaja RJ, P̈oyḧonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2005; 24: 131-41
67. Pater C, Bhatnagar D, Berrou J-P, et al. A novel approach to treatment of hypertension in diabetic patients: a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of eprosartan versus ramipril with low-dose hydrochlorothiazide and moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. Rationale and design [ISRCTN55725285]. Curr Control Trials Cardiovasc Med 2004 Oct 1; 5 (1): 9